ICLE 2022 | CD1c-restricted T cells as a potential immunotherapy for leukemia
Michela Consonni, PhD, San Raffaele Scientific Institute, Milan, Italy, discusses research relating to the identification of CD1c, a major histocompatibility complex (MHC) class I-like molecule, and its potential as a target against leukemia. CD1c autoreactive T-cells recognize methyl-lysophosphatidic acids (mLPAs), which are expressed on leukemic cells. As CD1c is additionally only expressed in hematopoietic cells, the risk of graft versus host disease (GvHD) is lowered, and lipid-specific T cells may subsequently provide an alternative to chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapy in patients with acute myeloid leukemia (AML). This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
